Lumida
/IMVT
⌘K
Immunovant Inc

Immunovant Inc

IMVT
$37.36USD-1.94%-0.74 today

MARKET CAP

7.7B

P/E (TTM)

FWD P/E

DAY RANGE

$37 – $39

52W RANGE

$15
$45

AI Summary

Stalk
TrimMedium

IMVT has decisively broken below a key horizontal support zone with a sharp red candle, confirming an active Support Failure pattern. Medium-term bias is bearish as broken support now acts as resistance under Stage 3 distribution conditions. Short-term execution is deferred—the price is extended below declining EMAs and RSI is in extreme oversold territory, suggesting waiting for a rally into EMAs before selling. The long-term uptrend remains intact above the rising 200-day SMA.

  • $797.8M cash as of June 30, 2026 provides runway for pivotal trials.
  • Upcoming IMVT-1402 Graves’ trial data readouts expected in 2026.
  • Q1 net loss of $0.75/share vs. $0.66 consensus highlights widening losses.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICTREND
Sales, Adj.
YoY %
P / Sales
EV / Sales
Gross Profit, Adj.
YoY %
Margin %
EV / Gross Profit
EBITDA, Adj.
YoY %
Margin %
EV / EBITDA
EBIT
YoY %
Margin %
EV / EBIT
Net Income
YoY %
Net Margin
EPS (GAAP)
YoY %